The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells

Haematologica

Volumn 92, Issue 3, 2007, Pages 349-356

  Ocaña, Esther ^a   Delgado Pérez, Luis ^a   Campos Caro, Antonio ^a   Muñóz, Juan ^a   Paz, Antonio ^b   Franco, Rafael ^c   Brieva, José A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^c Hospital del SAS   (Spain)

Author keywords

Chronic lymphocytic leukemia; CXCR3 expression by CLL B cells; Prognostic factors

Indexed keywords

CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CD38 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; CXC CHEMOKINE RECEPTOR 3; MEMBRANE PROTEIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER INFILTRATION; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE ANALYSIS; GENETIC CORRELATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; B CELL LEUKEMIA; BIOSYNTHESIS; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; NONPARAMETRIC TEST; PROPORTIONAL HAZARDS MODEL; SOMATIC HYPERMUTATION; SURVIVAL;

AGED; ANTIGENS, CD38; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, B-CELL, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CHEMOKINE; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247559223     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10649     Document Type: Article

References (30)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-34.
4. Rai. A critical analysis of staging in CLL. In: Gale RP, editor. Chronic lymphocytic leukemia: recent progress, future direction. Vol. 253. New York; 1987.
5. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
6. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004;103:1202-10.
7. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-127
8. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
9. Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999;104:115-121
10. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94:3658-67.
11. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000;95:627-632
12. Roy MP, Kim CH, Butcher EC. Cytokine control of memory B cell homing machinery. J Immunol 2002;169:1676-82.
13. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 2001;167:7084-93.
14. Sampalo A, Navas G, Medina F, Segundo C, Camara C, Brieva JA. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000;96:3168-74.
15. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002;99:2154-61.
16. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17: 2257-317.
17. Hamblin TJ, Davies Z, Gardiner A, Oscier DJ, Stevenson FK. Unmutated Ig VH genes are associated with more aggressive forms of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
18. Damie RN, Wasil T, Fais F, Ghiotto F, Valetta A, Allen SL, et al. IgV gene mutation status and CD38 expressionas novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
19. Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R, et al. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984;64:642-8.
20. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined to clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135-44.
21. Domingo-Domenech E, Domingo-Claros A, Gonzalez-Barca E, Beneitez D, Alonso E, Romagosa V, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002;87:1021-7.
22. Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005;19:750-8.
23. Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853-61.
24. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.
25. Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and a4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002;99:2977-84.
26. Ishibe N, Albitar M, Jilani IB, Goldin LR, Marti GE, Caporaso NE. CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. Blood 2002;100:1100-1.
27. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc 2004;79:318-25.
28. Barretina J, Junca J, Llano A, Gutierrez A, Flores A, Blanco J, et al. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 2003;82:500-5.
29. Dao-Ung LP, Sluyter R, Fuller SJ, Taper J, Wiley JS. CXCR4 but not CXCR3 expression correlates with lymphocyte counts in B-cell chronic lymphocytic leukemia. Ann Hematol 2004;83:326-7.
30. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004;104:502-8.